查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1714375

生物相似藥單株抗體市場－全球產業規模、佔有率、趨勢、機會和預測（按產品、應用、地區和競爭細分，2020-2030 年）

Biosimilar Monoclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球生物相似藥單株抗體市值為 54.7 億美元，預計到 2030 年將達到 108.3 億美元，複合年成長率為 12.03%。生物相似藥單株抗體（mAb）因其成本效益和與原創生物製劑相當的療效，成為生物製藥產業的一個變革性領域。隨著生物藥物在治療癌症、自體免疫疾病和發炎性疾病等疾病中變得越來越重要，生物相似藥 mAb 提供了一種有希望的替代方案，尤其是考慮到其價格實惠且易於獲得。儘管生物相似藥與參考生物製劑並不完全相同，但它們的安全性、功效和品質都經過精心設計，非常接近。它們透過活細胞中先進的重組 DNA 技術進行開發，使更廣泛的患者能夠獲得治療，並有助於降低醫療保健費用。隨著全球醫療保健系統努力應對高昂的生物製劑成本，生物相似藥 mAb 在保持治療效果的同時減輕經濟負擔的潛力而越來越受到關注。

市場概覽
預測期 2026-2030
2024年市場規模 54.7億美元
2030年市場規模 108.3億美元
2025-2030 年複合年成長率 12.03%
成長最快的領域 腫瘤學
最大的市場 北美洲

關鍵市場促進因素

癌症和自體免疫疾病發生率上升

主要市場挑戰

製造複雜性

主要市場趨勢

技術進步

主要市場參與者 * 雅培

  • 輝瑞
  • 諾華公司
  • 艾伯維公司
  • Coherus 生物科學公司
  • 百奧康有限公司
  • 艾爾建公司
  • Accord Healthcare 有限公司。
  • 安進公司
  • 雷迪博士的實驗室

生物相似藥單株抗體市場，依產品分類：

  • 英夫利西單抗
  • 利妥昔單抗
  • 阿昔單抗
  • 曲妥珠單抗
  • 阿達木單抗
  • 貝伐單抗
  • 其他

生物相似藥單株抗體市場按應用分類：

  • 腫瘤學
  • 慢性及自體免疫疾病
  • 其他

生物相似藥單株抗體市場（按地區）：

  • 北美洲
  • 亞太
  • 歐洲
  • 中東和非洲
  • 南美洲

競爭格局

公司簡介：對全球生物相似藥單株抗體市場的主要公司進行詳細分析。

可用的客製化：

公司資訊

  • 對其他市場參與者（最多五個）進行詳細分析和分析。

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球生物相似藥單株抗體市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 副產物（英夫利西單抗、利妥昔單抗、阿昔單抗、曲妥珠單抗、阿達木單抗、貝伐單抗等）
    • 按應用（腫瘤學、慢性及自體免疫疾病、其他）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美生物相似藥單株抗體市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲生物相似藥單株抗體市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太生物相似藥單株抗體市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲生物相似藥單株抗體市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲生物相似藥單株抗體市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Abbott
  • Pfizer
  • Novartis AG
  • AbbVie, Inc.
  • Coherus BioSciences
  • Biocon Limited
  • Allergan plc.
  • Accord Healthcare limited.
  • Amgen inc.
  • Dr. Reddy's Laboratory

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 15878

The Global Biosimilar Monoclonal Antibodies Market was valued at USD 5.47 billion in 2024 and is projected to reach USD 10.83 billion by 2030, expanding at a CAGR of 12.03%. Biosimilar monoclonal antibodies (mAbs) represent a transformative segment in the biopharmaceutical industry due to their cost-effective nature and comparable efficacy to originator biologics. As biologic drugs become increasingly essential in treating conditions like cancer, autoimmune, and inflammatory diseases, biosimilar mAbs offer a promising alternative, especially given their affordability and accessibility. Though biosimilars are not identical to reference biologics, they are engineered to closely match in safety, efficacy, and quality. Their development through advanced recombinant DNA technology in living cells enables broader patient access and helps mitigate healthcare expenditures. As healthcare systems globally grapple with high biologic costs, biosimilar mAbs are gaining traction for their potential to alleviate economic burdens while maintaining therapeutic outcomes.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 5.47 Billion
Market Size 2030USD 10.83 Billion
CAGR 2025-203012.03%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

Rising Cancer and Autoimmune Disorders

The global upsurge in cancer and autoimmune diseases has led to a growing demand for effective and affordable therapies, thereby propelling the biosimilar monoclonal antibodies (mAbs) market. Cancer, characterized by abnormal cell growth, continues to be a major cause of mortality, with the European Union reporting a 2.3% rise in new cases and a 2.4% increase in cancer-related deaths in 2022 compared to 2020. Similarly, autoimmune diseases are becoming more prevalent, heightening the necessity for targeted and cost-efficient treatments. Biosimilar mAbs have emerged as a valuable solution by providing therapeutic efficacy comparable to reference biologics at reduced costs. This market segment is increasingly crucial in balancing patient needs and healthcare affordability, driving its expansion in the global pharmaceutical landscape.

Key Market Challenges

Manufacturing Complexity

The production of biosimilar monoclonal antibodies (mAbs) is fraught with complexity due to their biological origins. These therapies are derived from living cells, introducing inherent variability in expression systems, cell lines, and culture conditions. Such variability can lead to slight differences between biosimilars and their reference biologics, complicating efforts to maintain consistent quality and biological performance. Ensuring equivalence in physicochemical properties, biological activity, and immunogenicity requires robust quality control and advanced analytical tools. Minor changes in the manufacturing process can significantly affect clinical outcomes, presenting a regulatory and developmental hurdle. This complexity results in higher development costs and prolonged timelines, emphasizing the need for substantial investments to achieve regulatory compliance and maintain product consistency.

Key Market Trends

Technological Advancements

Technological innovation is driving the evolution of biosimilar monoclonal antibodies (mAbs), transforming them into precision therapeutic tools. Advances in biotechnology and research have facilitated the development of biosimilars that closely replicate the safety and efficacy of originator biologics. These breakthroughs support the rise of personalized medicine by enabling therapies tailored to individual genetic and disease profiles. Concurrently, innovations in bioprocessing, such as enhanced cell culture methods and purification techniques, have significantly improved production efficiency and product quality. These developments not only reduce manufacturing costs but also ensure better patient outcomes. As a result, biosimilar mAbs are increasingly integrated into treatment regimens, bolstered by their improved accessibility, affordability, and alignment with modern medical strategies.

Key Market Players * Abbott

  • Pfizer
  • Novartis AG
  • AbbVie, Inc.
  • Coherus BioSciences
  • Biocon Limited
  • Allergan plc.
  • Accord Healthcare limited.
  • Amgen inc.
  • Dr. Reddy's Laboratory

Report Scope: In this report, the Global Biosimilar Monoclonal Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biosimilar Monoclonal Antibodies Market, By Product:

  • Infliximab
  • Rituximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab
  • Others

Biosimilar Monoclonal Antibodies Market, By Application:

  • Oncology
  • Chronic & Autoimmune Diseases
  • Others

Biosimilar Monoclonal Antibodies Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biosimilar Monoclonal Antibodies Market.

Available Customizations:

Global Biosimilar Monoclonal Antibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Biosimilar Monoclonal Antibodies Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab, Others)
    • 5.2.2. By Application (Oncology, Chronic & Autoimmune Diseases, Others)
    • 5.2.3. By Company (2024)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Biosimilar Monoclonal Antibodies Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biosimilar Monoclonal Antibodies Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Biosimilar Monoclonal Antibodies Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Biosimilar Monoclonal Antibodies Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Biosimilar Monoclonal Antibodies Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Biosimilar Monoclonal Antibodies Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Biosimilar Monoclonal Antibodies Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Biosimilar Monoclonal Antibodies Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Biosimilar Monoclonal Antibodies Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Biosimilar Monoclonal Antibodies Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia-Pacific Biosimilar Monoclonal Antibodies Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Biosimilar Monoclonal Antibodies Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Biosimilar Monoclonal Antibodies Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Biosimilar Monoclonal Antibodies Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Biosimilar Monoclonal Antibodies Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Biosimilar Monoclonal Antibodies Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. South America Biosimilar Monoclonal Antibodies Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Biosimilar Monoclonal Antibodies Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Biosimilar Monoclonal Antibodies Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Biosimilar Monoclonal Antibodies Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. Middle East and Africa Biosimilar Monoclonal Antibodies Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Biosimilar Monoclonal Antibodies Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Biosimilar Monoclonal Antibodies Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Biosimilar Monoclonal Antibodies Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Abbott
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Pfizer
  • 14.3. Novartis AG
  • 14.4. AbbVie, Inc.
  • 14.5. Coherus BioSciences
  • 14.6. Biocon Limited
  • 14.7. Allergan plc.
  • 14.8. Accord Healthcare limited.
  • 14.9. Amgen inc.
  • 14.10. Dr. Reddy's Laboratory

15. Strategic Recommendations

16. About Us & Disclaimer